Brandon Coder

Moderna Therapeutics (United States) — United States

Medicine · Health Sciences

9h-index518citations47works4.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(24), CAR-T cell therapy research(18), Immunotherapy and Immune Responses(17), Monoclonal and Polyclonal Antibodies Research(16), Immune Cell Function and Interaction(7)

Publications46 total

933 Preclinical proof-of-concept of an off-the-shelf mRNA cancer antigen therapy targeting pan-tumor antigens for the treatment of multiple solid tumors
Regular and Young Investigator Award Abstracts·2025Open Access
Supplementary Table 1 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2024Open Access
Supplementary Figure 3 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2024Open Access
Supplementary Figure 6 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2024Open Access
Supplementary Figure 8 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2024Open Access
Supplementary Table 2 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2024Open Access
Supplementary methods from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2024· 1 citedOpen Access
Supplementary Figure 7 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2024Open Access
Supplementary Table 3 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2024Open Access
Data from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2024Open Access
Supplementary Figure 2 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2024Open Access
Supplementary Table 4 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2024· 1 citedOpen Access
Supplementary Figure 1 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2024Open Access
Supplementary Figure 4 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2024Open Access
Peptide list and HLA types from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2024Open Access
Supplementary Figure 5 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
2024Open Access
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
Cancer Discovery·2024· 78 cited
1530 T-cell responses to individualized neoantigen therapy (INT) mRNA-4157 (V940) as monotherapy or in combination with pembrolizumab
2023· 3 citedOpen Access
Figure S3 from Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer
2023Open Access
Supplemental Material and Methods from Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Moomal Tasneem(18), Lauren Gerbereux(18), Andressa S. Laino(18), Joshua P. Frederick(18), Justin F. Gainor(17), Manish R. Patel(17), Jeffrey S. Weber(17), Julie E. Bauman(17), Jeffrey Clarke(17), Ricklie Julian(17), Aaron J. Scott(17), Kedar Kirtane(17), Céline Robert-Tissot(17), Wei Zheng(17), Filippos Porichis(17), Jack Pollard(17), Peijie Hou(17), Igor Feldman(17), Lakshmi Srinivasan(17), Praveen Aanur(17)